{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:18:14Z","timestamp":1788265094117,"version":"build-2803163510"},"reference-count":28,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3,4]]},"abstract":"<jats:p>Liposomal amphotericin B is an effective and safe alternative for the treatment of visceral leishmaniasis in the Indian subcontinent. In this study, we used a higher-dose regimen of an indigenously manufactured liposomal amphotericin B (FUNGISOME; L-AmBL), which was intended to improve the efficacy in terms of long-lasting cure rate. Thirty men and thirty women between 12 and 60 years old with parasitologically confirmed visceral leishmaniasis were enrolled in two cohorts of 15 patients each. Subjects in cohort I were administered one dose (10 mg\/kg body weight) of L-AmBL intravenously. After the safety at this dose was confirmed in cohort I, patients were recruited in cohort II. They received one infusion of an escalated dose (15 mg\/kg body weight). The safety of these two doses was evaluated over a period of 30 days, and efficacy was assessed for initial cure at day 30 and definitive cure at 6 months. FUNGISOME was found to be safe, with an initial cure rate of 100% at day 30 and a definitive cure rate of 93.3% at the 6-month follow-up in both the cohorts.<\/jats:p>","DOI":"10.4269\/ajtmh.14-0259","type":"journal-article","created":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T05:32:38Z","timestamp":1418707958000},"page":"513-517","source":"Crossref","is-referenced-by-count":43,"title":["Single-Dose Indigenous Liposomal Amphotericin B in the Treatment of Indian Visceral Leishmaniasis: A Phase 2 Study"],"prefix":"10.4269","volume":"92","author":[{"given":"Shyam","family":"Sundar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhukar","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2795","reference":[{"key":"R1","series-title":"Regional Strategic Framework for Elimination of Kala-Azar from South-East Asia Region (2005\u20132015)","author":"Searo","year":"2005"},{"key":"R2","series-title":"PLoS ONE","first-page":"e35671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012"},{"key":"R3","series-title":"Control of the Leishmaniasis. Report of a Meeting of the WHO Expert Committee on the Control of Leishmaniases","author":"World Health Organization","year":"2010"},{"key":"R4","series-title":"Indian J Med Res","first-page":"195","article-title":"Elimination of leishmaniasis (kala-azar) from the Indian subcontinent is technically feasible & operationally achievable","volume":"123","author":"Bhattacharya","year":"2006"},{"key":"R5","series-title":"Bull World Health Organ","first-page":"931","article-title":"Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison","volume":"72","author":"Thakur","year":"1994"},{"key":"R6","series-title":"Ann Trop Med Parasitol","first-page":"129","article-title":"A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis","volume":"98","author":"Thakur","year":"2004"},{"key":"R7","series-title":"Trans R Soc Trop Med Hyg","first-page":"319","article-title":"Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases","volume":"93","author":"Thakur","year":"1999"},{"key":"R8","series-title":"Clin Infect Dis","first-page":"377","article-title":"Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations","volume":"38","author":"Sundar","year":"2004"},{"key":"R9","series-title":"N Engl J Med","first-page":"504","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India","volume":"362","author":"Sundar","year":"2010"},{"key":"R10","series-title":"Bull World Health Organ","first-page":"25","article-title":"Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries","volume":"76","author":"Berman","year":"1998"},{"key":"R11","series-title":"Am J Trop Med Hyg","first-page":"143","article-title":"Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study","volume":"66","author":"Sundar","year":"2002"},{"key":"R12","series-title":"Clin Infect Dis","first-page":"800","article-title":"Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study","volume":"37","author":"Sundar","year":"2003"},{"key":"R13","series-title":"Clin Infect Dis","first-page":"608","article-title":"Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis","volume":"42","author":"Sundar","year":"2006"},{"key":"R14","series-title":"Trop Doct","first-page":"80","article-title":"Successful treatment of antimony-resistant visceral leishmaniasis with liposomal Amphotericin B in a child","volume":"25","author":"Karande","year":"1995"},{"key":"R15","series-title":"PLoS Negl Trop Dis","first-page":"e764","article-title":"A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy","volume":"4","author":"Mondal","year":"2010"},{"key":"R16","series-title":"Common Toxicity Criteria","author":"Program CTE","year":"2002"},{"key":"R17","series-title":"Am J Trop Med Hyg","first-page":"475","article-title":"Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis","volume":"32","author":"Chulay","year":"1983"},{"key":"R18","series-title":"Clin Infect Dis","first-page":"543","article-title":"Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use","volume":"55","author":"Sundar","year":"2012"},{"key":"R19","series-title":"Am J Trop Med Hyg","first-page":"66","article-title":"Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh","volume":"85","author":"Rahman","year":"2011"},{"key":"R20","series-title":"Clin Infect Dis","first-page":"1530","article-title":"Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance","volume":"56","author":"Rijal","year":"2013"},{"key":"R21","series-title":"Trans R Soc Trop Med Hyg","first-page":"350","article-title":"Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline","volume":"97","author":"Rijal","year":"2003"},{"key":"R22","series-title":"Clin Infect Dis","first-page":"1104","article-title":"Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic","volume":"31","author":"Sundar","year":"2000"},{"key":"R23","series-title":"Lancet Glob Health","first-page":"e51","article-title":"Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study","volume":"2","author":"Mondal","year":"2014"},{"key":"R24","series-title":"Trans R Soc Trop Med Hyg","first-page":"314","article-title":"Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis","volume":"93","author":"Bodhe","year":"1999"},{"key":"R25","series-title":"Antimicrob Agents Chemother","first-page":"3487","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study","volume":"45","author":"Walsh","year":"2001"},{"key":"R26","series-title":"BMJ","first-page":"419","article-title":"Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial","volume":"323","author":"Sundar","year":"2001"},{"key":"R27","series-title":"J Postgrad Med","first-page":"58","article-title":"Post-marketing study to assess the safety, tolerability and effectiveness of FungisomeTM: an Indian liposomal amphotericin B preparation","volume":"51","author":"Sanath","year":"2005"},{"key":"R28","series-title":"Ambisome (Amphotericin B) Liposome for Injection: Prescribing Information","author":"Astellas Pharma US, Inc.","year":"2012"}],"container-title":["The American Society of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/92\/3\/article-p513.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/92\/3\/article-p513.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/92\/3\/article-p513.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T19:28:03Z","timestamp":1723058883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/92\/3\/article-p513.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,4]]},"references-count":28,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.14-0259","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,4]]}}}